JAKARTA, Indonesia, April 11 /PRNewswire-FirstCall/ -- IDenta Corp. today released a recap of an important April trade mission made by company representatives to Indonesia. Two of the meetings were of special significance and included hands-on demonstrations with the country’s most important drug enforcement agencies, the National Narcotics Board of Indonesia (BNN) and Beau Dan Cukai HQ (the Indonesian Customs Authority).
Mr. Salmon Aviad from IDenta Corp, attended meetings with the company’s distributors PT Kurongkor Utama in Jakarta, Indonesia. “Each of meetings went extremely well,” reported Aviad Salmon. “The IDenta Stinger demonstration was performed perfectly. The executive director of BNN even tested for marijuana himself.”
Approximately 20 customs officers including high ranked officials, from the Narcotics and Psychotropic Department attended the second meeting at Bea Dan Cukai HQ (the Indonesian Customs Authority). At the end of each of the presentations, IDenta product suitcases were left for further substance testing.
A recent story in the Jakarta Post, www.thejakartapost.com, reported that a study involving the National Narcotics Agency and the University of Indonesia claimed Indonesians are spending more than Rp 12 trillion (US$ 1 billion ) on drugs.
For further information about the BNN please visit: http://www.bnn.go.id/
About Identa
IDenta Corporation is a leading developer of proprietary on-site drug detection kits used by governments and security forces around the world. Information concerning IDenta’s business plan and product line, including rapid test kits (substance only) for the detection of marijuana, hashish, ecstasy, cocaine, crack, heroin and methamphetamines may be found at www.IDenta.biz and www.drugsdetector.com
Certain of the statements contained herein may be, within the meaning of the federal securities laws, “forward-looking statements” that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management’s expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
For Investor Relations, lobbying interests or information concerning IDenta’s products internationally contact:
Yaacov Shoham, IDenta Corp., CEO Tel: +972-52-6554487, +972-8-9716874 Fax: +972-8-9716875 fpi@drugsdetector.com For Investor Relations in the United States contact: Randy Jacobs, SITCOM LLC IDentaNews@sitcomllc.com +1-800-316-9437
IDenta Corp.
CONTACT: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487,+972-8-9716874, Fax: +972-8-9716875, fpi@drugsdetector.com. For InvestorRelations in the United States contact: Randy Jacobs, SITCOM LLC,IDentaNews@sitcomllc.com, +1-800-316-9437
